Ming-Hei Tai

PharmOncology

Health EN ↓ 10 episodes

A podcast about pharmacy and oncology

Author

Ming-Hei Tai

Episodes

Why don't we have a pan-tumor drug that targets BRCA mutations? 08.07.2026 7:38

The challenges of targeting BRCA mutations in all cancers Tumor lineage shapes BRCA-mediated phenotypes: https://pmc.ncbi.nlm.nih.gov/articles/PMC7048239/

DESTINY-Breast11 and Surrogate Endpoints 01.07.2026 6:36

Thoughts on using pCR as a surrogate endpoint DESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/ Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant BMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381 FDA-sponsored analysis: https://pubmed.ncb...

The Fc region of antibodies 24.06.2026 9:22

Episode explaining the Fc receptor on antibodies, with some examples! Lessons from TIGIT antibodies: https://pubmed.ncbi.nlm.nih.gov/41389708/

CIRCULATE and ctDNA positivity rates 17.06.2026 8:33

Discussion on the CIRCULATE trial ASCO CIRCULATE abstract: https://www.asco.org/abstracts-presentations/260542 Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12847216/ ASCO GI abstract: Pathologic determinants of ctDNA-shedding in colorectal cancer metastases. https:...

The dangers of cross-trial comparisons 10.06.2026 7:42

Why it's hard to compare adverse events across trials Capitello-291: https://www.nejm.org/doi/full/10.1056/NEJMoa2214131 Capitello-281: https://pubmed.ncbi.nlm.nih.gov/41120017/

Thoughts on RASolute 302 (for 20 minutes) 03.06.2026 20:46

RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

ADC Sequencing and the "Sandwich" method 27.05.2026 9:06

What we do and do not understand about antibody drug conjugate sequencing. Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltext Post mortem sacituzumab govitecan study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/

Is HRR really a biomarker in prostate cancer? 20.05.2026 7:39

Why HRR gene mutations are not the perfect biomarker. PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltext TALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract TRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

Interpreting prospective ctDNA trials 15.05.2026 14:43

Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker

Why we should look at continuing CD38 antibodies after progression 06.05.2026 9:32

There is an explosion of trials in the CD38 antibody space (daratumumab, isatuximab) in multiple myeloma. This episode goes over one key unanswered question which many of the trials are not attempting to answer.